drugset / Trial / NCT00395343

Sitagliptin Added-on to Insulin Study (0431-051)

NCT00395343

Phase 3 Completed 641 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.

Timeline

Start
2006-12-11
Primary completion
2008-10-13
Completion
2008-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg